Sangamo announces positive Phase 1 data for HIV gene therapy
The trial aimed at blocking the virus so that patients do not need antiviral drugs, and was designed to evaluate the safety and clinical outcomes of Sangamo’s zinc
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.